enGene Holdings Inc. (NASDAQ:ENGNW) Sees Large Growth in Short Interest

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 200 shares, an increase of 100.0% from the February 13th total of 100 shares. Based on an average daily volume of 9,200 shares, the short-interest ratio is currently 0.0 days.

enGene Price Performance

ENGNW traded up $0.05 during mid-day trading on Friday, hitting $0.69. 5,402 shares of the stock were exchanged, compared to its average volume of 14,181. The firm’s fifty day moving average is $0.88 and its two-hundred day moving average is $1.25. enGene has a 1-year low of $0.42 and a 1-year high of $6.50.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.